Biomerica Inc Financials
Biomerica Inc (BMRA) reported $4.3M in revenue over the twelve months to Feb 28, 2026, down 23.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cost cuts narrowed losses, but thin gross profit still leaves the business dependent on outside financing.
From FY2023 to FY2025, revenue stayed near$5.3M while operating cash outflow shrank by about$1.6M , so the recent progress did not come from a bigger top line. Because gross margin remained under10.0% and SG&A plus R&D still totaled$5.64M in FY2025, the improvement points to a smaller expense base rather than stronger unit economics.
The balance sheet is debt-light: no long-term debt is reported and liabilities were only
The harder operating problem is gross profit scarcity: FY2025 gross profit was just
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Biomerica Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Biomerica Inc scores -12.14, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.2M) relative to total liabilities ($1.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Biomerica Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Biomerica Inc reported a net loss of $5.0M while operations used $3.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Biomerica Inc generated $5.3M in revenue in fiscal year 2025. This represents a decrease of 1.9% from the prior year.
Biomerica Inc's EBITDA was -$5.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.7% from the prior year.
Biomerica Inc reported -$5.0M in net income in fiscal year 2025. This represents an increase of 16.8% from the prior year.
Cash & Balance Sheet
Biomerica Inc held $3.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Biomerica Inc's gross margin was 9.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the prior year.
Biomerica Inc's operating margin was -96.7% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Biomerica Inc's net profit margin was -93.6% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Biomerica Inc's ROE was -121.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 30.4 percentage points from the prior year.
Capital Allocation
Biomerica Inc invested $1.0M in research and development in fiscal year 2025. This represents a decrease of 31.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BMRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $987K-18.4% | $1.2M-12.3% | $1.4M+84.2% | $749K-33.1% | $1.1M-31.6% | $1.6M-9.5% | $1.8M+61.6% | $1.1M |
| Cost of Revenue | $1.0M-11.0% | $1.2M+21.2% | $956K-4.0% | $996K-9.5% | $1.1M-8.3% | $1.2M-21.0% | $1.5M+38.6% | $1.1M |
| Gross Profit | -$44K-186.3% | $51K-88.0% | $424K+271.7% | -$247K-1400.0% | $19K-95.7% | $437K+51.2% | $289K+1156.5% | $23K |
| R&D Expenses | $178K-7.8% | $193K-9.0% | $212K-15.9% | $252K+16.1% | $217K-15.6% | $257K-13.5% | $297K+12.5% | $264K |
| SG&A Expenses | $1.1M-12.6% | $1.2M-7.4% | $1.3M+24.6% | $1.1M+5.4% | $1.0M-13.7% | $1.2M-13.8% | $1.4M+5.8% | $1.3M |
| Operating Income | -$1.3M+5.5% | -$1.4M-22.8% | -$1.1M+28.6% | -$1.6M-29.4% | -$1.2M-21.9% | -$993K+27.4% | -$1.4M+10.4% | -$1.5M |
| Income Tax | $8K+60.0% | $5K+66.7% | $3K-25.0% | $4K+200.0% | -$4K-33.3% | -$3K-175.0% | $4K-42.9% | $7K |
| Net Income | -$1.3M+0.6% | -$1.3M-66100.0% | $2K+100.1% | -$1.5M-32.8% | -$1.2M-22.4% | -$950K+27.8% | -$1.3M+7.4% | -$1.4M |
| EPS (Diluted) | -$0.44+2.2% | -$0.45 | $0.00+100.0% | -$1.98 | -$0.48 | -$0.06 | -$0.63 | -$2.57 |
Not reported in any period shown, so not listed: Interest Expense.
BMRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.9M-19.2% | $6.0M-12.0% | $6.9M+15.3% | $5.9M-19.4% | $7.4M+1.4% | $7.3M-7.6% | $7.9M-15.0% | $9.3M |
| Current Assets | $4.1M-20.6% | $5.2M-12.0% | $5.9M+21.0% | $4.9M-21.4% | $6.2M+4.4% | $5.9M-7.8% | $6.4M-16.6% | $7.7M |
| Cash & Equivalents | $1.3M-47.5% | $2.5M-16.7% | $3.1M-0.2% | $3.1M0.0% | $3.1M+28.9% | $2.4M-15.9% | $2.8M-32.4% | $4.2M |
| Inventory | $1.6M+7.9% | $1.5M+3.5% | $1.5M-1.1% | $1.5M-10.0% | $1.7M-7.5% | $1.8M-7.9% | $1.9M-18.3% | $2.4M |
| Accounts Receivable | $941K-0.6% | $947K-21.4% | $1.2M+64.8% | $731K-42.4% | $1.3M-4.4% | $1.3M-14.5% | $1.6M+63.8% | $947K |
| Total Liabilities | $1.6M-2.4% | $1.6M-5.9% | $1.7M-7.7% | $1.8M-0.1% | $1.8M-14.7% | $2.2M-14.4% | $2.5M-5.2% | $2.7M |
| Current Liabilities | $1.6M-2.4% | $1.6M-5.6% | $1.7M-2.7% | $1.7M+5.5% | $1.6M-12.1% | $1.9M-12.8% | $2.2M-2.4% | $2.2M |
| Total Equity | $3.3M-25.2% | $4.4M-14.0% | $5.2M+25.6% | $4.1M-25.8% | $5.5M+8.2% | $5.1M-4.3% | $5.3M-18.9% | $6.6M |
| Retained Earnings | -$55.8M-2.4% | -$54.5M-2.5% | -$53.2M0.0% | -$53.2M-3.0% | -$51.6M-2.3% | -$50.5M-1.9% | -$49.5M-2.7% | -$48.2M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BMRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3M-26.1% | -$991K-269.8% | -$268K+59.5% | -$661K+36.7% | -$1.0M-32.1% | -$791K+41.1% | -$1.3M-28.7% | -$1.0M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $24K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$1.1M |
| Investing Cash Flow | N/A | N/A | N/A | $0+100.0% | -$4K | N/A | N/A | -$24K |
| Financing Cash Flow | $61K-87.3% | $482K-47.6% | $920K+18500.0% | -$5K-100.3% | $1.7M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BMRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -4.5%-8.7pp | 4.2%-26.5pp | 30.7%+63.7pp | -33.0%-34.7pp | 1.7%-25.0pp | 26.7%+10.7pp | 16.0%+13.9pp | 2.1% |
| Operating Margin | -131.5% | -113.5% | -81.0% | -209.1% | -108.1% | -60.7%+15.0pp | -75.7% | -136.6% |
| Net Margin | -132.9% | -109.1% | 0.1% | -206.1% | -103.9% | -58.1%+14.8pp | -72.8% | -127.1% |
| Return on Equity | -39.6%-9.8pp | -29.8%-29.8pp | 0.0%+37.7pp | -37.6%-16.6pp | -21.0%-2.4pp | -18.6%+6.0pp | -24.6%-3.1pp | -21.6% |
| Return on Assets | -26.9%-5.0pp | -21.9%-21.9pp | 0.0%+26.0pp | -26.0%-10.2pp | -15.8%-2.7pp | -13.1%+3.7pp | -16.7%-1.4pp | -15.4% |
| Current Ratio | 2.64-0.6x | 3.25-0.2x | 3.48+0.7x | 2.80-1.0x | 3.76+0.6x | 3.17+0.2x | 3.00-0.5x | 3.51 |
| Debt-to-Equity | 0.47+0.1x | 0.360.0x | 0.33-0.1x | 0.45+0.1x | 0.33-0.1x | 0.420.0x | 0.47+0.1x | 0.40 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -95.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Biomerica Inc Ranks
Frequently Asked Questions
What is Biomerica Inc's annual revenue?
Biomerica Inc (BMRA) reported $5.3M in total revenue for fiscal year 2025. This represents a -1.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biomerica Inc's revenue growing?
Biomerica Inc (BMRA) revenue declined by 1.9% year-over-year, from $5.4M to $5.3M in fiscal year 2025.
Is Biomerica Inc profitable?
No, Biomerica Inc (BMRA) reported a net income of -$5.0M in fiscal year 2025, with a net profit margin of -93.6%.
What is Biomerica Inc's EBITDA?
Biomerica Inc (BMRA) had EBITDA of -$5.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biomerica Inc's gross margin?
Biomerica Inc (BMRA) had a gross margin of 9.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Biomerica Inc's operating margin?
Biomerica Inc (BMRA) had an operating margin of -96.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biomerica Inc's net profit margin?
Biomerica Inc (BMRA) had a net profit margin of -93.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biomerica Inc's return on equity (ROE)?
Biomerica Inc (BMRA) has a return on equity of -121.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biomerica Inc's operating cash flow?
Biomerica Inc (BMRA) recorded an outflow of $3.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Biomerica Inc's total assets?
Biomerica Inc (BMRA) had $5.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Biomerica Inc spend on research and development?
Biomerica Inc (BMRA) invested $1.0M in research and development during fiscal year 2025.
What is Biomerica Inc's current ratio?
Biomerica Inc (BMRA) had a current ratio of 2.80 as of fiscal year 2025, which is generally considered healthy.
What is Biomerica Inc's debt-to-equity ratio?
Biomerica Inc (BMRA) had a debt-to-equity ratio of 0.45 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biomerica Inc's return on assets (ROA)?
Biomerica Inc (BMRA) had a return on assets of -83.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Biomerica Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Biomerica Inc (BMRA) held $3.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.8M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Biomerica Inc's Altman Z-Score?
Biomerica Inc (BMRA) has an Altman Z-Score of -12.14, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Biomerica Inc's Piotroski F-Score?
Biomerica Inc (BMRA) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biomerica Inc's earnings high quality?
Biomerica Inc (BMRA) reported a net loss of $5.0M while operations used $3.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Biomerica Inc?
Biomerica Inc (BMRA) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.